<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>GTI-2040 is a 20-mer oligonucleotide that is complementary to a coding region in the <z:chebi fb="2" ids="33699">mRNA</z:chebi> of the R2 small subunit component of human <z:chebi fb="0" ids="26561">ribonucleotide</z:chebi> reductase </plain></SENT>
<SENT sid="1" pm="."><plain>In vitro studies using a number of human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines have demonstrated that GTI-2040 decreases <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein levels of R2 in a sequence- and target-specific manner </plain></SENT>
<SENT sid="2" pm="."><plain>In vivo studies have shown that GTI-2040 significantly inhibits growth of human <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumors</z:e> (<z:mp ids='MP_0009308'>adenocarcinoma</z:mp>), <z:mp ids='MP_0009153'>pancreatic tumors</z:mp> (<z:mp ids='MP_0009308'>adenocarcinoma</z:mp>), <z:e sem="disease" ids="C0023903" disease_type="Neoplastic Process" abbrv="">liver tumors</z:e>, <z:hpo ids='HP_0100526'>lung tumors</z:hpo>, <z:e sem="disease" ids="C1458155" disease_type="Neoplastic Process" abbrv="">breast tumors</z:e> (<z:mp ids='MP_0009308'>adenocarcinoma</z:mp>), <z:hpo ids='HP_0009726'>renal tumors</z:hpo>, <z:mp ids='MP_0008000'>ovarian tumors</z:mp> (<z:mp ids='MP_0009308'>adenocarcinoma</z:mp>), <z:hpo ids='HP_0002861'>melanoma</z:hpo>, brain <z:hpo ids='HP_0100843'>glioblastoma</z:hpo>-<z:hpo ids='HP_0009592'>astrocytoma</z:hpo>, prostatic <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, and <z:e sem="disease" ids="C0007873" disease_type="Neoplastic Process" abbrv="">cervical tumors</z:e> in <z:mp ids='MP_0003815'>nude</z:mp> and/or severe combined immunodeficient mice </plain></SENT>
<SENT sid="3" pm="."><plain>Antitumor effects were not observed with an oligonucleotide containing four mismatches to the R2 sequence or with a scrambled sequence containing the same base content but not complementary to R2 </plain></SENT>
<SENT sid="4" pm="."><plain>This suggests that an antisense mechanism is responsible for the in vivo observations </plain></SENT>
<SENT sid="5" pm="."><plain>In addition to <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> assays, GTI-2040 was tested in a murine model of human <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Treatment of severe combined immunodeficient mice bearing Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> with GTI-2040, but not control oligonucleotides, greatly extended the survival of mice, and survival extended well beyond the treatment period </plain></SENT>
<SENT sid="7" pm="."><plain>Finally, GTI-2040 specifically inhibits <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> of human <z:hpo ids='HP_0002861'>melanoma</z:hpo> cells to the lungs in <z:mp ids='MP_0003815'>nude</z:mp> mice </plain></SENT>
<SENT sid="8" pm="."><plain>Taken together, the results of these studies indicate that GTI-2040 can act as a selective and specific anticancer agent against a broad range of human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
</text></document>